Drugs

, Volume 61, Issue 11, pp 1599–1624 | Cite as

Insulin Glargine

A Review of its Therapeutic Use as a Long-Acting Agent for the Management of Type 1 and 2 Diabetes Mellitus
Adis Drug Evaluation

Summary

Abstract

Insulin glargine is a recombinant human insulin analogue produced by DNA technology using a nonpathogenic strain of Escherichia coli. Two modifications of human insulin result in a stable molecule which is soluble in slightly acidic conditions (pH 4.0) and precipitates in the neutral pH of subcutaneous tissue. Because of these properties, absorption of insulin glargine is delayed and the analogue provides a fairly constant, basal insulin supply without peaks in plasma insulin levels for approximately 24 hours, similar to that achieved by a continuous subcutaneous insulin infusion.

Insulin glargine is indicated as a once daily subcutaneous injection to provide basal glycaemic control in adults and children aged >6 years with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Fasting plasma glucose and fasting blood glucose levels generally improved to a greater extent in patients with type 1 diabetes mellitus receiving insulin glargine than patients who administered Neutral Protamine Hagedorn (NPH) insulin. In patients with type 1 or 2 disease, glycosylated haemoglobin levels were slightly reduced and to a similar extent with insulin glargine and NPH insulin. Most clinical trials in patients with type 1 or 2 diabetes mellitus demonstrated a lower incidence of hypoglycaemia, especially nocturnal hypoglycaemia, compared with NPH insulin.

One of the most common adverse events with insulin glargine treatment was injection site pain which, in some studies, occurred more frequently than in patients receiving NPH insulin. In all cases the symptoms were mild and treatment discontinuation was not required. Otherwise, the drug is well tolerated and does not appear to be immunogenic.

Conclusions: Insulin glargine once a day provides basal control of glycaemia for approximately 24 hours without inducing peaks in plasma insulin levels in patients with type 1 or 2 diabetes mellitus. In long term, well designed trials insulin glargine once daily improved glycaemic control at least as effectively as NPH insulin given once or twice daily. The drug was well tolerated and in most studies the incidence of nocturnal hypoglycaemia was significantly less in patients treated with insulin glargine compared with patients receiving NPH insulin. Therefore, insulin glargine is likely to be a useful addition to the armamentarium of insulin therapy by establishing basal glycaemic control with once daily administration and a reduced risk of nocturnal hypoglycaemia.

Pharmacodynamic Properties

Insulin glargine is manufactured by recombinant DNA technology. Modifications to the structure of natural human insulin produce an analogue with a stable hexameric form and an altered isoelectric point from a pH of 5.4 to 6.7. These changes enable insulin glargine to remain soluble in the slightly acidic pH of the vial (pH 4.0) and precipitate in the neutral pH of subcutaneous tissue after injection where it has a delayed absorption and a prolonged duration of action relative to other exogenous basal insulins. The addition of a small amount of zinc (30 mg/L) to the insulin glargine formulation is necessary for crystallisation in the subcutaneous tissue and further delays the absorption time.

A single daily, subcutaneous injection of insulin glargine provides basal insulin requirements in patients with type 1 diabetes mellitus. Blood glucose levels recorded over a 24-hour period following a subcutaneous injection of insulin glargine were similar to those observed when the patient was given 4 doses of Neutral Protamine Hagedorn (NPH) insulin over 1 day. The metabolic effect of insulin glargine increased to a plateau within 4 hours and then remained more constant than that of NPH insulin, as evidenced by a lower area under the curve analysis for glucose consumption, at all time-points throughout a 24-hour period following a single insulin dose. Insulin glargine does not cause a peak effect but has a constant concentration/effect versus time profile which lasts 24 hours and was similar to that achieved by a continuous subcutaneous infusion of insulin lispro.

In healthy volunteers and/or patients, equal doses of insulin glargine and regular human insulin, given as short intravenous infusions, produced similar effects on plasma glucose lowering, symptomatic responses to hypoglycaemia, suppression of hepatic glucose output and lipolysis. Insulin glargine appears to have no effect on immune response.

In vitro, insulin glargine has a slightly increased insulin-like growth factor 1 (IGF-1) receptor affinity and mitogenic potency compared with regular human insulin, but a many-fold less binding affinity for IGF-1 receptors than endogenous IGF-1. In vivo, insulin glargine appears to exert mitogenic and growth-promoting activity similar to regular human insulin. Toxicity studies of insulin glargine in rats and mice for periods up to 24 months showed no histological evidence of mammary gland tumour development.

Pharmacokinetic Properties

The rate of absorption of insulin glargine provides a basal plasma insulin level which remains constant for at least 24 hours. The mean time to disappearance of 25% radioactivity from the subcutaneous injection site was twice as long for insulin glargine as for NPH insulin. The mean percentage of residual radioactivity remaining at the injection site of insulin glargine at 24 hours was almost twice that for NPH insulin. Similar rates of absorption of insulin glargine containing zinc 30 mg/L (standard formulation) were measured from the abdomen, thigh and deltoid subcutaneous injection sites.

There was no evidence of accumulation after repeated injections of insulin glargine. The drug is partly metabolised in subcutaneous tissue to form 2 active metabolites with in vivo and in vitro activity similar to that of human insulin.

Clinical Efficacy

Large, well designed trials of 4 to 52 weeks’ duration in over 5000 adults and children with type 1 diabetes mellitus and adults with type 2 diabetes mellitus have shown that a single daily injection of insulin glargine provides glycaemic control for approximately 24 hours with a lower incidence of nocturnal hypoglycaemia than NPH insulin.

In patients with type 1 diabetes mellitus, insulin glargine caused a greater reduction of fasting plasma glucose (FPG) and fasting blood glucose (FBG) levels and a similar reduction of glycosylated haemoglobin (HbA1c) levels compared with patients receiving NPH insulin (FPG levels not reported in children).

FPG levels were significantly decreased from baseline to end-point in patients with type 1 diabetes mellitus receiving insulin glargine, whereas levels remained stable or decreased slightly in patients who administered NPH insulin.

A greater reduction in FPG and FBG levels was evident in patients receiving insulin glargine who had administered NPH insulin twice daily prior to the trial than those previously receiving NPH insulin once daily. This was despite these patients having lower baseline glucose levels than patients on once daily NPH insulin. The same patients, randomised to insulin glargine, also showed a greater reduction from baseline in basal insulin requirements throughout the study than patients on a once daily NPH regimen prior to the trial. In contrast, patients randomised to NPH insulin had a gradual increase in insulin dose from baseline to end-point.

The improvement in FPG and FBG levels was evident as early as the first week and was sustained throughout the trial period, whereas the beneficial effect of NPH took longer to develop.

Variability in self-monitored FBG levels declined more in patients with type 1 disease receiving insulin glargine than NPH insulin.

Overall, the incidence of nocturnal hypoglycaemia was significantly less in patients with type 1 diabetes mellitus receiving insulin glargine than NPH insulin, particularly patients who administered NPH insulin once daily. Episodes of symptomatic hypoglycaemia occurred frequently in insulin glargine and NPH insulin treatment groups in patients with type 1 disease and overall the incidence was similar. Overnight plasma glucose profiles were generally stable in patients with type 1 diabetes mellitus receiving insulin glargine, whereas patients who administered NPH insulin had an increase in blood glucose levels after 5am.

In clinical trials of patients with type 2 diabetes mellitus, FPG, FBG and HbA1 clevels were reduced from baseline to a similar extent with both insulin glargine and NPH insulin.

In most studies the incidence of nocturnal hypoglycaemia was significantly less in patients with type 2 diabetes mellitus who received insulin glargine compared with NPH insulin. Symptomatic hypoglycaemia was also lower in the insulin glargine groups than the NPH insulin groups but, overall, the difference was not as large as for nocturnal hypoglycaemia. The between-group difference in symptomatic hypoglycaemia was significant when compared with insulin-naive patients randomised to NPH insulin.

Insulin glargine produced greater treatment satisfaction than NPH insulin in patients with type 1 and 2 diabetes mellitus. In a 6-month study of patients with type 1 disease, treatment satisfaction improved in the insulin glargine group but deteriorated slightly in the NPH insulin group. Patients with type 2 diabetes mellitus showed improved treatment satisfaction over a 1 year study in both the insulin glargine and NPH insulin groups. At week 36 and endpoint the improvement was greater in the insulin glargine group compared with NPH insulin.

Tolerability

The incidence of adverse events in patients treated with insulin glargine is similar to that in patients treated with NPH insulin. In some studies, reactions at the injection site occurred more often in patients receiving insulin glargine than those receiving NPH insulin, whereas other studies reported a similar incidence in insulin glargine and NPH insulin groups. In all cases, the injection site reaction was mild and discontinuation of the drug was not required. Patient withdrawals from clinical trials relating to treatment were few and there were no significant differences between treatment groups in this parameter.

There was no evidence of an increased immunogenic response to insulin glargine compared with NPH insulin. An increase in antibody levels from pretreatment levels was reported in some long term trials for both insulin glargine and NPH insulin, but was found to be higher in the NPH insulin group. The clinical relevance of insulin antibodies remains unclear. No clinically relevant changes in Escherichia coli antibody formation were observed. Compared with NPH insulin, insulin glargine was associated with a similar or lower increase in bodyweight gain. Similarly, insulin glargine did not carry an increased risk for the development or progression of diabetic retinopathy compared with NPH insulin.

Dosage and Administration

Insulin glargine is self-administered subcutaneously once daily to provide basal insulin levels. It is indicated for use in adults with type 1 or 2 diabetes mellitus and, in the US only, is also indicated for use in children aged >6 years with type 1 disease. Administration is via a conventional insulin syringe or an injection pen. Insulin glargine must not be diluted or mixed with other insulin formulations. Rolling or shaking of the vial prior to administration is not required as insulin glargine is available as a clear solution.

The dosage of insulin glargine is determined individually for each patient based on previous insulin therapy, if any, and blood glucose levels. In a study of patients with type 2 diabetes mellitus with no previous treatment with insulin, insulin glargine was started at an average dose of 10U once daily. Dosage was then adjusted according to patient blood glucose levels and average daily doses ranged from 2 to 100U. Patients transferred to insulin glargine from a once daily injection of NPH insulin generally require the same initial dose. To reduce the risk of hypoglycaemia the manufacturer recommends that the initial dose of insulin glargine be reduced by approximately 20% for the first week of treatment in patients previously receiving NPH insulin or long-acting insulin twice daily. Ongoing dosage should then be adjusted based on blood glucose levels. Medical supervision is recommended during transfer and the early weeks of treatment. Paediatric patients should be managed in the same way. The timing and dosage of additional short-acting insulin or oral antidiabetic agents may need to be adjusted.

As for other insulin injections, rotation of the site should be managed so that one site within an area is not injected more than once every 1 to 2 weeks. Similar rates of absorption of insulin glargine occur from abdominal, thigh and deltoid regions.

It is recommended that the dosage of insulin glargine be reduced in patients with renal or hepatic impairment, followed by careful monitoring of blood glucose levels. Initial dosage and titration should be conservative in the elderly.

References

  1. 1.
    Mandrap-Poulsen T. Diabetes. BMJ 1998 Apr 18; 316: 1221–5CrossRefGoogle Scholar
  2. 2.
    IDF. Diabetes prevalence [online]. Available from: URL: http://www.idf.org [Accessed 2001 Jul]
  3. 3.
    WHO. Diabetes Mellitus Fact sheet no. 138 [online]. Available from: URL: http://www.who.int/inff Accessed2001 Apr]
  4. 4.
    Songer TJ, Zimmet PZ. Epidemiology of type II diabetes: an international perspective. Pharmacoeconomics 1995; 8 Suppl. 1: 1–11PubMedCrossRefGoogle Scholar
  5. 5.
    Rosenbloom AL, Joe JR, Young RS, et al. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999 Feb; 22(2): 345–54PubMedCrossRefGoogle Scholar
  6. 6.
    Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 Sep 30; 329(14): 977–86CrossRefGoogle Scholar
  7. 7.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12; 352: 837–53CrossRefGoogle Scholar
  8. 8.
    Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial. J Pediatr 1994 Aug; 125(2): 177–88CrossRefGoogle Scholar
  9. 9.
    Lee WL, Zinman B. From insulin to insulin analogs: progress in the treatment of type 1 diabetes. Diabetes Rev 1998; 6(2): 73–88Google Scholar
  10. 10.
    Park G. The clinical use of insulin glargine in type 2 diabetes. Proceedings of the HMR Symposium 34th Jahrestagung Dt Diabetes Ges; 1999 May; Frankfurt, 22–23Google Scholar
  11. 11.
    Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327(20): 1426–33PubMedCrossRefGoogle Scholar
  12. 12.
    Pieber TR. Long acting insulin analogues: can they provide a basal insulin level? J Pediatr Endocrinol Metab 1999; 12 3: 745–50Google Scholar
  13. 13.
    Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 1999; 35: 307–35PubMedCrossRefGoogle Scholar
  14. 14.
    Lando H. The new ‘designer’ insulins. Clin Diabetes 2000; 18(4): 154–60Google Scholar
  15. 15.
    Gillies PS, Figgitt DP, Lamb HM. Insulin glargine. Drugs 2000 Feb; 59: 253–60, discussion 261–2PubMedCrossRefGoogle Scholar
  16. 16.
    Bolli GB, Di Marchi RD, Park GD, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999 Oct; 42: 1151–67PubMedCrossRefGoogle Scholar
  17. 17.
    Home P. Insulin glargine: the first clinically useful extended-acting insulin in half a century? Expert Opin Invest Drug 1999 Mar; 8: 307–14CrossRefGoogle Scholar
  18. 18.
    Mohn A, Dunger DB. Insulin therapy in children and adolescents with type 1 diabetes. Curr Paediatr 1999; 9: 158–63CrossRefGoogle Scholar
  19. 19.
    Aventis Pharmaceuticals Inc. Prescribing information: insulin glargine [rDNA origin] injection. 2000 Apr; Kansas City (KS)Google Scholar
  20. 20.
    Scipke G, Berchthold H, Geisen K, et al. HOE901 — a new insulin with prolonged action [abstract]. Eur J Endocrinol 1995 Apr; 132 Suppl. 1:25Google Scholar
  21. 21.
    Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000 Dec; 49: 2142–8PubMedCrossRefGoogle Scholar
  22. 22.
    Talaulicar M, Willms B, Rosskamp R. HOE 901, a new insulin analogue, for substitution of basal insulin requirement in type I diabetes [in German]. Diabetes Stoffwechsel 1996; 5: 3–6Google Scholar
  23. 23.
    Dagogo-Jack S, Askari H, Lehner LL. Effect of glargine on glucose disposal and lipolysis in healthy and diabetic subjects [abstract no. 1737]. Diabetes 2000 May; 49 Suppl. 1: 213Google Scholar
  24. 24.
    Dagogo-Jack S, Askari H, Morrill B, et al. Physiological responses during hypoglycaemia induced by regular human insulin or a novel human analogue, insulin glargine. Diabetes, Obes Metab 2000; 2: 373–83CrossRefGoogle Scholar
  25. 25.
    Mohn A, Strang S, Wernicke-Panten K, et al. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care 2000 Apr; 23: 557–9PubMedCrossRefGoogle Scholar
  26. 26.
    Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000 May; 23: 644–9PubMedCrossRefGoogle Scholar
  27. 27.
    Soon PC, Matthews DR, Rosskamp R, et al. 24h profile of action of biosynthetic long-acting insulin (HOE901) tested in normal volunteers by glucose clamp methodology [abstract no. 0621]. Diabetes 1997 May; 46 Suppl. 1: 161AGoogle Scholar
  28. 28.
    Meyer BH, Scholtz HE, Pretorius SG, et al. A comparison of the pharmacodynamics (glucose lowering effect) of intravenous HOE901 and regular insulin using the euglycaemic clamp technique [abstract no. PII-33]. Clin Pharmacol Ther 2000 Feb; 67(2): 123Google Scholar
  29. 29.
    Mohideen P, Mudaliar S, Deutsch R, et al. Characterization of glucose turnover of insulin glargine in comparison with regular human insulin in healthy male subjects [abstract no. 879]. 35th Annual Meeting of the European Association Study Diabetes (EASD), Brussels. Diabetologia 1999 1999 Sep/Oct; 42 Suppl. 1: A234Google Scholar
  30. 30.
    Scholtz HE, van Niekerk N, Meyer BH, et al. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique [abstract no. 882]. Diabetologia 1999; 42 Suppl. 1: A235Google Scholar
  31. 31.
    Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000 Jun; 49: 999–1005PubMedCrossRefGoogle Scholar
  32. 32.
    Bolli GB, Owens DR. Insulin glargine. Lancet 2000 Aug 5; 356: 443–5PubMedCrossRefGoogle Scholar
  33. 33.
    Bähr M, Kolter T, Scipke G, et al. Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31,ArgB32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997 Feb 12; 320: 259–65PubMedCrossRefGoogle Scholar
  34. 34.
    Ciaraldi T, Carter L, Mudaliar S, et al. Effects of the long acting insulin analog insulin glargine on cultured human skeletal muscle cells; comparisons with insulin and IGF-1 [abstract no. 1736-PO]. Diabetes 2001 Jun; 50 Suppl. 2: 416Google Scholar
  35. 35.
    Sandow J, Scipke G. In vitro pharmacology studies with insulin glargine and human insulin: IGF-1 receptor binding and thymidine incorporation [abstract no. 1787-PO]. Diabetes 2001 Jun; 50 Suppl. 2: 429Google Scholar
  36. 36.
    Berti L, Kellerer M, Bossenmaier B, et al. The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B 10) and regular insulin. Horm Metab Res 1998; 30: 123–9PubMedCrossRefGoogle Scholar
  37. 37.
    Scipke G, Sandow J. Effects of insulin glargine, human insulin and the insulin analog Asp(B10) on the insulin receptor signaling cascade [abstract no. 525-P]. Diabetes 2001 June; 50 Suppl. 2: 132Google Scholar
  38. 38.
    Kellerer M, Haring HU. Insulin analogues: impact of cell model characteristics on results and conclusions regarding mitogenic properties. Exp Clin Endocrinol Diabetes 2001; 109: 63–4PubMedCrossRefGoogle Scholar
  39. 39.
    Stammberger I, Troschau G, Donaubauer H. Insulin glargine is not carcinogenic in rats and mice [abstract no. 1788-PO]. Diabetes 2001 June; 50 Suppl. 2: 429Google Scholar
  40. 40.
    Luzio SD, Owens D, Evans M, et al. Comparison of the sc absorption of HOE 901 and NPH human insulin type 2 diabetic subjects [abstract]. Diabetes 1999 May; 48 Suppl. 1: 111Google Scholar
  41. 41.
    Owens DR, Coates PA, Luzio SD, et al. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men. Diabetes Care 2000 Jun; 23: 813–9PubMedCrossRefGoogle Scholar
  42. 42.
    Heise T, Bott S, Rave K, et al. No evidence for accumulation of HOE901 after multiple injections in type I diabetic patients. Diabetologia 2000; 43 Suppl. 1: A196Google Scholar
  43. 43.
    Scipke G, Sandow J, Geisen K, et al. Preclinical profile of the new long-acting insulin glargine (HOE 901) [abstract no. P1-283]. 81st Annual Meeting of the Endocrine Society; 2000 Jun 21; Toronto (ON)Google Scholar
  44. 44.
    Sandow J, Scipke G, Kuerzel GU, et al. Pharmacokinetics and metabolism of insulin glargine [abstract no. P1-358]. 82nd Annual Meeting of the Endocrine Society; 2001; Denver (CO)Google Scholar
  45. 45.
    Pieber TR, Eugène-Jolchine I, Derobert E, et al. Efficacy and safety of HOE 901 versus NPH insulin in patients with type I diabetes. Diabetes Care 2000; 23(2): 157–62PubMedCrossRefGoogle Scholar
  46. 46.
    Rosenstock J, Park G, Zimmerman J, et al. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000 Aug;23: 1137–42PubMedCrossRefGoogle Scholar
  47. 47.
    Matthews DR, Pfeiffer C. Comparative clinical trial of a new long-acting insulin (HOE901) vs protamine insulin demonstrates less nocturnal hypoglycaemia. Multicentre HOE901 Research Group [abstract no 0394]. Diabetes 1998 May; 47 Suppl. 1: A101Google Scholar
  48. 48.
    Raskin P, Park G, Zimmerman J. The effect of HOE 901 on glycemic control in type 2 diabetes [abstract]. Diabetes 1998 May; 47 Suppl. 1: A103Google Scholar
  49. 49.
    American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1998 Jan; 21 Suppl. 1:S23–31CrossRefGoogle Scholar
  50. 50.
    Hershon K, Blevins T, Donley D, et al. Lower fasting blood glucose (FBG) and less symptomatic hypoglycemia with QD insulin glargine (Lantus) compared to BID NPH in subjects with type 1 diabetes [abstract 466-P]. Diabetes 2001 Jun; 50 Suppl. 2: 116–7Google Scholar
  51. 51.
    Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000 May; 23: 639–43PubMedCrossRefGoogle Scholar
  52. 52.
    Standl E. Results of an international, multicentred, randomised 28 week study for the comparison of glargine insulin (HOE 901) and NPH insulin in the intensified treatment (ICT) of type 1 diabetics [abstract no. pFr107]. Exp Clin Endocrinol Diabetes 2000; 108 Suppl. 1: 159Google Scholar
  53. 53.
    Raskin P, Klaff L, Bergenstal R, et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000 Nov; 23: 1666–71PubMedCrossRefGoogle Scholar
  54. 54.
    Schoenle E. Insulin glargine (HOE 901) lowers fasting blood glucose in children with type I diabetes mellitus without increasing the risk of hypoglycaemia [abstract no. 883]. Diabetologia 1999; 42 Suppl. 1: A235Google Scholar
  55. 55.
    Aventis Pharmaceuticals Inc. 2001; (Data on file)Google Scholar
  56. 56.
    Rosenstock J, Schwartz SL, Clark C, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001 Apr; 24(4): 631–6PubMedCrossRefGoogle Scholar
  57. 57.
    Fonseca V, Bell D, Mecca T. Less symptomatic hypoglycemia with bedtime insulin glargine (Lantus) compared to bedtime NPH insulin in patients with type 2 diabetes [abstract no. 449-P]. Diabetes 2001 Jun; 50 Suppl. 2: 112–3Google Scholar
  58. 58.
    Massi Benedetti M. Results of a 12 month study: insulin glargine (HOE 901) in combination with oral agents (pre-EASD Symp, Brussels) [abstract]. 35th Annual Meeting of the European Association Study Diabetes (EASD); 1999 Sep; BrusselsGoogle Scholar
  59. 59.
    Yki-Jarvinen H, Dressier A, Ziemen M, et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000 Aug; 23: 1130–6PubMedCrossRefGoogle Scholar
  60. 60.
    Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabetic Med. In pressGoogle Scholar
  61. 61.
    Witthaus E, Stewart J, Bradley C. Improved psychological outcomes after initiation of insulin treatment in patients with type II diabetes, [abstract no. 787]. Diabetologia 2000; 43 Suppl. 1: A205Google Scholar
  62. 62.
    Moriyama H, Nagata M, Fujihira K, et al. Treatment with human analog (GlyA21,ArgB32,ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes [letter]. Diabetes Care 2001 Feb; 24(2): 411–2PubMedCrossRefGoogle Scholar
  63. 63.
    Working Group. HOE 901 Retinopathy Expert Statement [Data on file]. 1999 Aug 5Google Scholar
  64. 64.
    Thrailkill KM, Quattrin T, Baker L, et al. Cotherapy with recombinant human insulin-like growth factor 1 and insulin improves glycemic control in type 1 diabetes. Diabetes Care 1999 Apr; 22(4): 585–92PubMedCrossRefGoogle Scholar
  65. 65.
    Peters K, Garg SK, Jackson WE, et al. Diabetic retinopathy in patients with type 1 diabetes treated with insulin glargine or NPH [abstract no. 1851-PO]. Diabetes 2001 June; 50 Suppl. 2: 443Google Scholar
  66. 66.
    Werner U. Evaluation of the hypoglycemic activity of a mixture of regular human insulin and insulin analog HOE 901 injected subcutaneously in healthy conscious dogs. Aventis Pharma Deutschland GmbH, DG Metabolic Diseases, H 821 (Data on file)Google Scholar
  67. 67.
    AHFS Drug Information. Insulin glargine. Am J Health System Pharm 2000 Nov 1; 57: 1961Google Scholar
  68. 68.
    Meltzer S, Leiter L, Daneman D, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Can Med Assoc J 1998; 159 Suppl. 8: S1–29Google Scholar
  69. 69.
    Berger M. Safety of insulin glargine [letter]. Lancet 2000 Dec 9; 356: 2013–4PubMedCrossRefGoogle Scholar
  70. 70.
    EMEA [online]. Available from: URL: http://www.emea.eu.int [Accessed 2001 Aug]

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Adis International limitedMairangi Bay, AucklandNew Zealand

Personalised recommendations